Pang-Dian Fan
Overview
Explore the profile of Pang-Dian Fan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
715
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Braso-Maristany F, Ferrero-Cafiero J, Falato C, Martinez-Saez O, Cejalvo J, Margeli M, et al.
Nat Commun
. 2024 Jul;
15(1):5826.
PMID: 38992028
Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3/HER3 levels. This research investigates the genetic factors affecting HER3-DXd's response in women...
2.
Mok T, Janne P, Nishio M, Novello S, Reck M, Steuer C, et al.
Future Oncol
. 2023 Dec;
20(15):969-980.
PMID: 38095056
After disease progression on EGFR tyrosine kinase inhibitor (TKI) therapy, patients with -mutated NSCLC who are then treated with platinum-based chemotherapy (PBC) obtain only limited clinical benefit with transient responses....
3.
Yu H, Goto Y, Hayashi H, Felip E, Yang J, Reck M, et al.
J Clin Oncol
. 2023 Sep;
41(35):5363-5375.
PMID: 37689979
Purpose: Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor...
4.
Yu H, Yang J, Hayashi H, Goto Y, Felip E, Reck M, et al.
Future Oncol
. 2023 May;
19(19):1319-1329.
PMID: 37212796
Limited treatment options exist for -mutated NSCLC that has progressed after EGFR TKI and platinum-based chemotherapy. HER3 is highly expressed in -mutated NSCLC, and its expression is associated with poor...
5.
Paik P, Fan P, Qeriqi B, Namakydoust A, Daly B, Ahn L, et al.
J Thorac Oncol
. 2022 Oct;
18(4):516-526.
PMID: 36240971
Introduction: Increased insight into the mutational landscape of squamous cell lung cancers (LUSCs) in the past decade has not translated into effective targeted therapies for patients with this disease. NRF2,...
6.
Sato H, Kubota D, Qiao H, Jungbluth A, Rekhtman N, Schoenfeld A, et al.
JCO Precis Oncol
. 2022 Aug;
6:e2200088.
PMID: 35952318
Purpose: The identification of novel oncogenic driver alterations and novel mechanisms of acquired resistance (AR) is the key for further development of personalized therapy. The current study investigates the potential...
7.
Pascual T, Oliveira M, Ciruelos E, Bellet Ezquerra M, Saura C, Gavila J, et al.
Front Oncol
. 2021 May;
11:638482.
PMID: 33968735
Preclinical data support a key role for the human epidermal growth factor receptor 3 (HER3) pathway in hormone receptor (HR)-positive breast cancer. Recently, new HER3 directed antibody drug conjugates have...
8.
Fan P, Yu H
Clin Cancer Res
. 2018 Aug;
24(22):5499-5501.
PMID: 30135146
Multiple members of the ERBB/HER family of the receptor tyrosine kinases have been implicated in mediating acquired resistance to EGFR inhibitors that are used to treat -mutant lung cancers. New...
9.
Fan P, Narzisi G, Jayaprakash A, Venturini E, Robine N, Smibert P, et al.
Proc Natl Acad Sci U S A
. 2018 Jun;
115(26):E6030-E6038.
PMID: 29875142
In ∼30% of patients with -mutant lung adenocarcinomas whose disease progresses on EGFR inhibitors, the basis for acquired resistance remains unclear. We have integrated transposon mutagenesis screening in an -mutant...
10.
Spraggon L, Martelotto L, Hmeljak J, Hitchman T, Wang J, Wang L, et al.
J Pathol
. 2017 Feb;
242(1):102-112.
PMID: 28188619
Chromosomal rearrangements encoding oncogenic fusion proteins are found in a wide variety of malignancies. The use of programmable nucleases to generate specific double-strand breaks in endogenous loci, followed by non-homologous...